Amphastar Pharmaceuticals saw a rise in profit margin from 18% to 21%, driven by increased revenue. Despite beating revenue estimates, EPS fell short. Future revenue growth is forecasted at 11% annually. One warning sign was identified. Contact Simply Wall St for feedback.